Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2005 Jun 30;60(9):747–753. doi: 10.1136/thx.2005.043695

Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A2

D Shoseyov 1, H Bibi 1, S Offer 1, O Schwob 1, M Krimsky 1, M Kleiman 1, S Yedgar 1
PMCID: PMC1747528  PMID: 15994250

Abstract

Background: The pathophysiology of asthma involves the action of inflammatory/allergic lipid mediators formed following membrane phospholipid hydrolysis by phospholipase A2 (PLA2). Cysteinyl leukotrienes are considered potent inducers of bronchoconstriction and airway remodelling. Ovalbumin (OVA) induced bronchoconstriction in rats is associated with increased secretory PLA2 (sPLA2) activation and cysteinyl leukotriene production, together with suppression of cytosolic PLA2 and prostaglandin E2. These processes are reversed when the animals are pretreated systemically with an extracellular cell impermeable sPLA2 inhibitor which also suppresses the early allergic reaction to OVA challenge. In this study we examine the capacity of the sPLA2 inhibitor to ameliorate inflammatory and allergic manifestations (early and late bronchoconstriction) of OVA induced allergic bronchitis in rats when the inhibitor was administered by inhalation to confine it to the airways.

Methods: Rats sensitised with OVA were treated with the sPLA2 inhibitor hyaluronic acid-linked phosphatidyl ethanolamine (HyPE). The rats were divided into four groups (n = 10 per group): (1) naïve controls (no sensitisation/no treatment); (2) positive controls (sensitisation + challenge with OVA inhalation and subcutaneous injection of 1 ml saline before each challenge; (3) sensitisation + challenge with OVA and HyPE inhalation before every challenge; and (4) sensitisation + challenge with OVA and treatment with subcutaneous dexamethasone (300 µg) before each challenge as a conventional reference. Another group received no treatment with HyPE during the sensitisation process but only before or after challenge of already sensitised rats. Pulmonary function was assessed and changes in the histology of the airways, levels of cysteinyl leukotrienes in BAL fluid, and the production of nitric oxide (No) and tumour necrosis factor α (TNFα) by BAL macrophages were determined.

Results: Inhalation of HyPE markedly suppressed OVA induced early and late asthmatic reactions as expressed by bronchoconstriction, airway remodelling (histology), cysteinyl leukotriene level in BAL fluid, and production of TNFα and NO by BAL macrophages. OVA induced bronchoconstriction in sensitised non-pretreated rats was also inhibited by inhalation of HyPE either before or after the challenge.

Conclusions: These findings confirm the pivotal role of sPLA2 in the pathophysiology of both the immediate allergic response and the inflammatory asthmatic process. Control of airway sPLA2 may be a new therapeutic approach to the treatment of asthma.

Full Text

The Full Text of this article is available as a PDF (219.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balsinde J., Balboa M. A., Insel P. A., Dennis E. A. Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol. 1999;39:175–189. doi: 10.1146/annurev.pharmtox.39.1.175. [DOI] [PubMed] [Google Scholar]
  2. Balsinde J., Balboa M. A., Yedgar S., Dennis E. A. Group V phospholipase A(2)-mediated oleic acid mobilization in lipopolysaccharide-stimulated P388D(1) macrophages. J Biol Chem. 2000 Feb 18;275(7):4783–4786. doi: 10.1074/jbc.275.7.4783. [DOI] [PubMed] [Google Scholar]
  3. Beck G. Ch, Yard B. A., Schulte J., Oberacker R., van Ackern K., van Der Woude F. J., Krimsky M., Kaszkin M., Yedgar S. Inhibition of LPS-induced chemokine production in human lung endothelial cells by lipid conjugates anchored to the membrane. Br J Pharmacol. 2002 Apr;135(7):1665–1674. doi: 10.1038/sj.bjp.0704618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beck Grietje Ch, Hermes Wilhelm C., Yard Benito A., Kaszkin Marietta, von Zabern Detlef, Schulte Jutta, Haak Markus, Prem Katharina, Krimsky W., van Ackern Klaus. Amelioration of endotoxin-induced sepsis in rats by membrane anchored lipid conjugates. Crit Care Med. 2003 Jul;31(7):2015–2021. doi: 10.1097/01.CCM.0000074717.46748.64. [DOI] [PubMed] [Google Scholar]
  5. Capper E. A., Marshall L. A. Mammalian phospholipases A(2): mediators of inflammation, proliferation and apoptosis. Prog Lipid Res. 2001 May;40(3):167–197. doi: 10.1016/s0163-7827(01)00002-9. [DOI] [PubMed] [Google Scholar]
  6. Coleman J. W. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin Exp Immunol. 2002 Jul;129(1):4–10. doi: 10.1046/j.1365-2249.2002.01918.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Coté Michele L., Kardia Sharon L. R., Wenzlaff Angela S., Ruckdeschel John C., Schwartz Ann G. Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer. JAMA. 2005 Jun 22;293(24):3036–3042. doi: 10.1001/jama.293.24.3036. [DOI] [PubMed] [Google Scholar]
  8. Dan P., Dagan A., Krimsky M., Pruzanski W., Vadas P., Yedgar S. Inhibition of type I and type II phospholipase A2 by phosphatidyl-ethanolamine linked to polymeric carriers. Biochemistry. 1998 Apr 28;37(17):6199–6204. doi: 10.1021/bi972066l. [DOI] [PubMed] [Google Scholar]
  9. Dan P., Nitzan D. W., Dagan A., Ginsburg I., Yedgar S. H2O2 renders cells accessible to lysis by exogenous phospholipase A2: a novel mechanism for cell damage in inflammatory processes. FEBS Lett. 1996 Mar 25;383(1-2):75–78. doi: 10.1016/0014-5793(96)00227-x. [DOI] [PubMed] [Google Scholar]
  10. Diaz Bruno L., Arm Jonathan P. Phospholipase A(2). Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):87–97. doi: 10.1016/s0952-3278(03)00069-3. [DOI] [PubMed] [Google Scholar]
  11. Diccianni M. B., Mistry M. J., Hug K., Harmony J. A. Inhibition of phospholipase A2 by heparin. Biochim Biophys Acta. 1990 Oct 1;1046(3):242–248. doi: 10.1016/0005-2760(90)90237-r. [DOI] [PubMed] [Google Scholar]
  12. Fonteh A. N., Marion C. R., Barham B. J., Edens M. B., Atsumi G., Samet J. M., High K. P., Chilton F. H. Enhancement of mast cell survival: a novel function of some secretory phospholipase A(2) isotypes. J Immunol. 2001 Oct 15;167(8):4161–4171. doi: 10.4049/jimmunol.167.8.4161. [DOI] [PubMed] [Google Scholar]
  13. Hamelmann E., Schwarze J., Takeda K., Oshiba A., Larsen G. L., Irvin C. G., Gelfand E. W. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):766–775. doi: 10.1164/ajrccm.156.3.9606031. [DOI] [PubMed] [Google Scholar]
  14. Hanasaki Kohji, Arita Hitoshi. Phospholipase A2 receptor: a regulator of biological functions of secretory phospholipase A2. Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:71–82. doi: 10.1016/s0090-6980(02)00022-9. [DOI] [PubMed] [Google Scholar]
  15. Holgate Stephen T., Peters-Golden Marc, Panettieri Reynold A., Henderson William R., Jr Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol. 2003 Jan;111(1 Suppl):S18–S36. doi: 10.1067/mai.2003.25. [DOI] [PubMed] [Google Scholar]
  16. Katoh Shigeki, Matsumoto Nobuhiro, Kawakita Kumiko, Tominaga Akira, Kincade Paul W., Matsukura Shigeru. A role for CD44 in an antigen-induced murine model of pulmonary eosinophilia. J Clin Invest. 2003 May;111(10):1563–1570. doi: 10.1172/JCI16583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Krimsky M., Yedgar S., Aptekar L., Schwob O., Goshen G., Gruzman A., Sasson S., Ligumsky M. Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor. Am J Physiol Gastrointest Liver Physiol. 2003 Apr 30;285(3):G586–G592. doi: 10.1152/ajpgi.00463.2002. [DOI] [PubMed] [Google Scholar]
  18. Lloret S., Moreno J. J. Ca2+ influx, phosphoinositide hydrolysis, and histamine release induced by lysophosphatidylserine in mast cells. J Cell Physiol. 1995 Oct;165(1):89–95. doi: 10.1002/jcp.1041650112. [DOI] [PubMed] [Google Scholar]
  19. Muñoz Nilda M., Kim Young Jun, Meliton Angelo Y., Kim Kwang Pyo, Han Sang-Kyou, Boetticher Evan, O'Leary Eileen, Myou Shigeharu, Zhu Xiangdong, Bonventre Joseph V. Human group V phospholipase A2 induces group IVA phospholipase A2-independent cysteinyl leukotriene synthesis in human eosinophils. J Biol Chem. 2003 Jun 9;278(40):38813–38820. doi: 10.1074/jbc.M302476200. [DOI] [PubMed] [Google Scholar]
  20. Nitzan D. W., Nitzan U., Dan P., Yedgar S. The role of hyaluronic acid in protecting surface-active phospholipids from lysis by exogenous phospholipase A(2). Rheumatology (Oxford) 2001 Mar;40(3):336–340. doi: 10.1093/rheumatology/40.3.336. [DOI] [PubMed] [Google Scholar]
  21. Pavord I. D., Tattersfield A. E. Bronchoprotective role for endogenous prostaglandin E2. Lancet. 1995 Feb 18;345(8947):436–438. doi: 10.1016/s0140-6736(95)90409-3. [DOI] [PubMed] [Google Scholar]
  22. Pinto Florence, Brenner Talma, Dan Phyllis, Krimsky Miron, Yedgar Saul. Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation. Glia. 2003 Dec;44(3):275–282. doi: 10.1002/glia.10296. [DOI] [PubMed] [Google Scholar]
  23. Proudfoot Amanda E. I., Power Christine A., Rommel Christian, Wells Timothy N. C. Strategies for chemokine antagonists as therapeutics. Semin Immunol. 2003 Feb;15(1):57–65. doi: 10.1016/s1044-5323(02)00128-8. [DOI] [PubMed] [Google Scholar]
  24. Russell A. L. Glycoaminoglycan (GAG) deficiency in protective barrier as an underlying, primary cause of ulcerative colitis, Crohn's disease interstitial cystitis and possibly Reiter's syndrome. Med Hypotheses. 1999 Apr;52(4):297–301. doi: 10.1054/mehy.1997.0652. [DOI] [PubMed] [Google Scholar]
  25. Schnitzer E., Dagan A., Krimsky M., Lichtenberg D., Pinchuk I., Shinar H., Yedgar S. Interaction of hyaluronic acid-linked phosphatidylethanolamine (HyPE) with LDL and its effect on the susceptibility of LDL lipids to oxidation. Chem Phys Lipids. 2000 Feb;104(2):149–160. doi: 10.1016/s0009-3084(99)00121-8. [DOI] [PubMed] [Google Scholar]
  26. Thomas P. S. Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol. 2001 Apr;79(2):132–140. doi: 10.1046/j.1440-1711.2001.00980.x. [DOI] [PubMed] [Google Scholar]
  27. Toews Myron L., Ediger Tracy L., Romberger Debra J., Rennard Stephen I. Lysophosphatidic acid in airway function and disease. Biochim Biophys Acta. 2002 May 23;1582(1-3):240–250. doi: 10.1016/s1388-1981(02)00177-4. [DOI] [PubMed] [Google Scholar]
  28. Triggiani Massimo, Granata Francescopaolo, Balestrieri Barbara, Petraroli Angelica, Scalia Giulia, Del Vecchio Luigi, Marone Gianni. Secretory phospholipases A2 activate selective functions in human eosinophils. J Immunol. 2003 Mar 15;170(6):3279–3288. doi: 10.4049/jimmunol.170.6.3279. [DOI] [PubMed] [Google Scholar]
  29. Tsukahara Y., Morisaki T., Horita Y., Torisu M., Tanaka M. Phospholipase A2 mediates nitric oxide production by alveolar macrophages and acute lung injury in pancreatitis. Ann Surg. 1999 Mar;229(3):385–392. doi: 10.1097/00000658-199903000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Vadas P., Browning J., Edelson J., Pruzanski W. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat. 1993 Aug;8(1):1–30. [PubMed] [Google Scholar]
  31. Vancheri Carlo, Mastruzzo Claudio, Sortino Maria Angela, Crimi Nunzio. The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol. 2004 Jan;25(1):40–46. doi: 10.1016/j.it.2003.11.001. [DOI] [PubMed] [Google Scholar]
  32. Wenzel S. E. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy. 1997 Jan-Feb;17(1 Pt 2):3S–12S. [PubMed] [Google Scholar]
  33. Yedgar S., Lichtenberg D., Schnitzer E. Inhibition of phospholipase A(2) as a therapeutic target. Biochim Biophys Acta. 2000 Oct 31;1488(1-2):182–187. doi: 10.1016/s1388-1981(00)00120-7. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES